Identification
NameBeraprost
Accession NumberDB05229
TypeSmall Molecule
GroupsInvestigational
Description

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII35E3NJJ4O6
CAS number88430-50-6
WeightAverage: 420.4738
Monoisotopic: 420.191268713
Chemical FormulaC24H29NaO5
InChI KeyYTCZZXIRLARSET-VJRSQJMHSA-M
InChI
InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;/t15?,17-,19+,20+,21-,23-;/m0./s1
IUPAC Name
sodium 4-[(2S,3R,4R,6S)-4-hydroxy-3-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-9-yl]butanoate
SMILES
[Na+].[H][C@]12C[C@@H](O)[[email protected]](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C1=CC=CC(CCCC([O-])=O)=C1O2
Pharmacology
Indication

For the treatment of pulmonary hypertension.

Structured Indications Not Available
Pharmacodynamics

Beraprost is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. Comparative data from a large randomised trial indicated that the drug appears as effective as ticlopidine in patients with these conditions. In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. Limited data suggest some efficacy with long-term beraprost treatment of patients with PAH, where options are few and where oral administration of the drug could be a considerable advantage over intravenous prostacyclin (PGI2) therapy.

Mechanism of action

Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca2+ from intracellular storage sites. This reduction in the influx of Ca2+ has been postulated to cause relaxation of the smooth muscle cells and vasodilation.

TargetKindPharmacological actionActionsOrganismUniProt ID
Prostacyclin receptorProteinunknownNot AvailableHumanP43119 details
Related Articles
Absorption

Oral bioavailability is 50–70%.

Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life

35–40 minutes

ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabBeraprost may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Beraprost can be increased when it is combined with Abiraterone.Approved
AceclofenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Aceclofenac.Approved
AcenocoumarolBeraprost may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Beraprost is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Adapalene.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Beraprost.Approved, Investigational
AlteplaseBeraprost may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Beraprost is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Beraprost.Approved
AncrodBeraprost may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe therapeutic efficacy of Beraprost can be decreased when used in combination with HMPL-004.Investigational
AnisodamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Anisodamine.Investigational
AnistreplaseBeraprost may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Antipyrine.Approved
Antithrombin III humanBeraprost may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Beraprost is combined with Apixaban.Approved
ApocyninThe therapeutic efficacy of Beraprost can be decreased when used in combination with Acetovanillone.Investigational
ApremilastThe therapeutic efficacy of Beraprost can be decreased when used in combination with Apremilast.Approved, Investigational
AprotininThe therapeutic efficacy of Beraprost can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinBeraprost may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanBeraprost may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Beraprost is combined with Balsalazide.Approved, Investigational
BecaplerminBeraprost may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBeraprost may increase the anticoagulant activities of Bemiparin.Approved
BenoxaprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Benoxaprofen.Withdrawn
Betulinic AcidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Betulinic Acid.Investigational
BivalirudinBeraprost may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BromfenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bucillamine.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Beraprost.Investigational
CangrelorBeraprost may increase the anticoagulant activities of Cangrelor.Approved
CarbamazepineThe metabolism of Beraprost can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe metabolism of Beraprost can be decreased when combined with Celecoxib.Approved, Investigational
CertoparinBeraprost may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Trisalicylate-choline.Approved
CilostazolCilostazol may increase the anticoagulant activities of Beraprost.Approved
Citric AcidBeraprost may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClonixinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe metabolism of Beraprost can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Beraprost can be decreased when combined with Clotrimazole.Approved, Vet Approved
CurcuminThe therapeutic efficacy of Beraprost can be decreased when used in combination with Curcumin.Investigational
Dabigatran etexilateBeraprost may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Beraprost can be decreased when it is combined with Dabrafenib.Approved
DalteparinBeraprost may increase the anticoagulant activities of Dalteparin.Approved
DarexabanBeraprost may increase the anticoagulant activities of Ym150.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Beraprost.Approved, Investigational
DeferasiroxThe serum concentration of Beraprost can be increased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Beraprost.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Beraprost is combined with Deoxycholic Acid.Approved
DesirudinBeraprost may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseBeraprost may increase the anticoagulant activities of Desmoteplase.Investigational
DextranBeraprost may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Beraprost may increase the anticoagulant activities of Dextran 40.Approved
DiclofenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicoumarolBeraprost may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Beraprost is combined with Diflunisal.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Beraprost.Approved
DitazoleBeraprost may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaBeraprost may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Beraprost can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ebselen.Investigational
Edetic AcidBeraprost may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBeraprost may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Beraprost can be decreased when combined with Efavirenz.Approved, Investigational
EnoxaparinBeraprost may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Beraprost.Approved, Investigational
EpirizoleThe therapeutic efficacy of Beraprost can be decreased when used in combination with Epirizole.Approved
EpoprostenolEpoprostenol may increase the antiplatelet activities of Beraprost.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Beraprost.Approved, Investigational
EtanerceptThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etanercept.Approved, Investigational
Ethyl biscoumacetateBeraprost may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
FelodipineThe metabolism of Beraprost can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fenoprofen.Approved
FibrinolysinBeraprost may increase the anticoagulant activities of Plasmin.Investigational
FloctafenineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluindioneBeraprost may increase the anticoagulant activities of Fluindione.Investigational
FlurbiprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FondaparinuxBeraprost may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumBeraprost may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosphenytoinThe metabolism of Beraprost can be increased when combined with Fosphenytoin.Approved
GabexateBeraprost may increase the anticoagulant activities of Gabexate.Investigational
GemfibrozilThe metabolism of Beraprost can be decreased when combined with Gemfibrozil.Approved
GlucosamineGlucosamine may increase the antiplatelet activities of Beraprost.Approved
HeparinBeraprost may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Higenamine.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Beraprost.Approved
IbudilastIbudilast may increase the anticoagulant activities of Beraprost.Approved, Investigational
IbuprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Beraprost can be decreased when used in combination with Icatibant.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Beraprost.Approved, Nutraceutical
IfenprodilIfenprodil may increase the anticoagulant activities of Beraprost.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of Beraprost.Approved, Investigational
IndobufenBeraprost may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indoprofen.Withdrawn
IrbesartanThe metabolism of Beraprost can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Beraprost.Investigational
KetoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ketorolac.Approved
LapatinibThe metabolism of Beraprost can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LepirudinBeraprost may increase the anticoagulant activities of Lepirudin.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Beraprost.Approved
LisofyllineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lisofylline.Investigational
LopinavirThe metabolism of Beraprost can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lornoxicam.Approved
LosartanThe metabolism of Beraprost can be decreased when combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Loxoprofen.Approved
LumacaftorThe serum concentration of Beraprost can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Beraprost can be decreased when used in combination with Masoprocol.Approved
Meclofenamic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Beraprost is combined with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Beraprost can be decreased when used in combination with Metamizole.Withdrawn
MifepristoneThe serum concentration of Beraprost can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Beraprost.Approved
MizoribineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mizoribine.Investigational
Mycophenolate mofetilThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nabumetone.Approved
NadroparinBeraprost may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Naftifine.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Beraprost.Investigational
NaproxenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nepafenac.Approved
Niflumic AcidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Niflumic Acid.Approved
NilotinibThe metabolism of Beraprost can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Beraprost is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Beraprost is combined with Obinutuzumab.Approved
OlopatadineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Beraprost is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Beraprost.Approved, Nutraceutical
OxaprozinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OzagrelBeraprost may increase the anticoagulant activities of Kct 0809.Investigational
ParecoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Parecoxib.Approved
ParnaparinBeraprost may increase the anticoagulant activities of Parnaparin.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Beraprost.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Beraprost.Approved, Investigational
PhenindioneBeraprost may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Beraprost can be increased when combined with Phenobarbital.Approved
PhenprocoumonBeraprost may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Beraprost can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PioglitazoneThe metabolism of Beraprost can be decreased when combined with Pioglitazone.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pirfenidone.Investigational
PiroxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PrasugrelBeraprost may increase the anticoagulant activities of Prasugrel.Approved
PrimidoneThe metabolism of Beraprost can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Beraprost can be decreased when used in combination with Propacetamol.Approved
Protein S humanBeraprost may increase the anticoagulant activities of Protein S human.Approved
PTC299The therapeutic efficacy of Beraprost can be decreased when used in combination with PTC299.Investigational
QuinineThe metabolism of Beraprost can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Beraprost can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Beraprost.Investigational
ResveratrolThe therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol.Experimental, Investigational
ReteplaseBeraprost may increase the anticoagulant activities of Reteplase.Approved
ReviparinBeraprost may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Beraprost.Approved
RifampicinThe metabolism of Beraprost can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Beraprost can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Beraprost can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanBeraprost may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe metabolism of Beraprost can be decreased when combined with Rosiglitazone.Approved, Investigational
SalicylamideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Beraprost is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salsalate.Approved
SecobarbitalThe metabolism of Beraprost can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagBeraprost may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Beraprost can be decreased when used in combination with Seratrodast.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Beraprost.Approved, Vet Approved
SRT501The therapeutic efficacy of Beraprost can be decreased when used in combination with SRT501.Investigational
StiripentolThe metabolism of Beraprost can be decreased when combined with Stiripentol.Approved
StreptokinaseBeraprost may increase the anticoagulant activities of Streptokinase.Approved
SulfamethoxazoleThe metabolism of Beraprost can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Sulindac.Approved
SulodexideBeraprost may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
TamoxifenThe metabolism of Beraprost can be decreased when combined with Tamoxifen.Approved
TenecteplaseBeraprost may increase the anticoagulant activities of Tenecteplase.Approved
TenoxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tenoxicam.Approved
TeriflunomideThe metabolism of Beraprost can be decreased when combined with Teriflunomide.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Beraprost.Investigational
Tiaprofenic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorBeraprost may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Beraprost.Approved
TinoridineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tinoridine.Investigational
TinzaparinBeraprost may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Beraprost.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Beraprost.Approved
Tolfenamic AcidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolmetin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.Approved
TranilastThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tranilast.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Beraprost.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Beraprost.Approved, Investigational
TriflusalBeraprost may increase the anticoagulant activities of Triflusal.Approved
TrimethoprimThe metabolism of Beraprost can be decreased when combined with Trimethoprim.Approved, Vet Approved
UrokinaseBeraprost may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Beraprost.Approved, Nutraceutical, Vet Approved
VorapaxarBeraprost may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinBeraprost may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBeraprost may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH: Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol. 2008 Feb;214(2):434-41. [PubMed:17620284 ]
  2. Melian EB, Goa KL: Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107-33. [PubMed:11790158 ]
External Links
ATC CodesB01AC19 — Beraprost
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (15.1 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Adult Males / Pharmacokinetics of TRK-100-STP1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentRenal Insufficiency,Chronic1
4TerminatedPreventionType 2 Diabetes Mellitus1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00811 mg/mLALOGPS
logP3.81ALOGPS
logP3.6ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)4.2ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area89.82 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity123.56 m3·mol-1ChemAxon
Polarizability44.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8736
Blood Brain Barrier+0.7754
Caco-2 permeable+0.5868
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor INon-inhibitor0.9641
P-glycoprotein inhibitor IINon-inhibitor0.9395
Renal organic cation transporterNon-inhibitor0.9342
CYP450 2C9 substrateNon-substrate0.7409
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.5132
CYP450 1A2 substrateInhibitor0.5177
CYP450 2C9 inhibitorNon-inhibitor0.8578
CYP450 2D6 inhibitorNon-inhibitor0.8834
CYP450 2C19 inhibitorNon-inhibitor0.7827
CYP450 3A4 inhibitorInhibitor0.6633
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7365
Ames testAMES toxic0.5331
CarcinogenicityNon-carcinogens0.9445
BiodegradationNot ready biodegradable0.5301
Rat acute toxicity3.6575 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8871
hERG inhibition (predictor II)Non-inhibitor0.9611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as coumarans. These are compounds containing the coumaran skeleton, which consists of a benzene ring fused to a 2,3-dihydrofuran ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassCoumarans
Sub ClassNot Available
Direct ParentCoumarans
Alternative ParentsAlkyl aryl ethers / Benzenoids / Secondary alcohols / Cyclic alcohols and derivatives / Carboxylic acid salts / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organic zwitterions / Organic sodium salts
SubstituentsCoumaran / Alkyl aryl ether / Benzenoid / Cyclic alcohol / Carboxylic acid salt / Secondary alcohol / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Uniprot Name:
Prostacyclin receptor
Molecular Weight:
40955.485 Da
References
  1. Melian EB, Goa KL: Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107-33. [PubMed:11790158 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Fukazawa T, Yajima K, Miyamoto Y: Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008 Oct;128(10):1459-65. [PubMed:18827466 ]
Drug created on October 21, 2007 16:24 / Updated on August 02, 2017 17:06